As soon as 48 hours,* NEMLUVIO relieves itch fast, with skin healing that lasts¹

Name: Nemluvio HCP
Creator: Nemluvio

Fast Itch Relief¹

See how NEMLUVIO^® significantly improved itch in both pivotal and long-term studies¹

VIEW THE DATA

Lasting Skin Healing¹

Discover how NEMLUVIO healed most PN nodules for patients with PN¹

SEE THE DIFFERENCE

Sleep Improvement²

Patients saw meaningful improvements in their sleep while taking NEMLUVIO²

VIEW THE DATA

Favorable Safety Profile³

NEMLUVIO offers a favorable safety profile and requires no preliminary lab evaluations or ongoing lab monitoring³

REVIEW SAFETY PROFILE

A Trial Program Designed to Capture the Complexity of PN^2,3

Explore the design of OLYMPIA, the largest controlled clinical trial program in PN⁴

REVIEW TRIAL

Experiencing a new reality

See how Chris relieved his unrelenting itch and achieved lasting skin healing with NEMLUVIO

Transcript

PN absolutely stalled five years of my life. My life would come to a standstill to scratch. You're talking about five years’ worth of damage from the PN, I feel like.

I was probably the first patient in the US to get NEMLUVIO. The change has been hard to believe. In a good way. Basically, before the shot, itching was part of my reality.

I have not been itching since the first shot. Since taking NEMLUVIO, I am finally itch free. And I feel like I'm living in a new reality at this point.

My wife, she's definitely noticed the difference. She's happy to see that I am not itching anymore.

My skin has cleared up a little bit. My skin, I feel like, was in horrible shape before these shots started. But I have noticed some results going the right direction with my skin.

My journey with PN has been a very long and difficult road. It absolutely does, after five years, feel good to find a medication that finally works.

Sign up now for more information about NEMLUVIO for PN

SIGN UP

PP-NRS response defined as a ≥4-point improvement from baseline. Data from Phase 3 clinical study (OLYMPIA 2) post hoc descriptive analysis of daily PP-NRS improvement; consistent results seen in OLYMPIA 1. Significant improvement was achieved at 48 hours (15% vs 3% with placebo, P≤0.005).^1,2

PN=prurigo nodularis; PP-NRS=Peak Pruritus Numerical Rating Scale.

References: 1. Galderma Laboratories, LP.; data on file. 2. Galderma Laboratories, L.P.; data on file. Clinical Study Report RD.06.SRE.203065 [OLYMPIA 2]; September 2023. 3. NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P. 4. Galderma phase Ill data published in The New England Journal of Medicine: full Olympia 2 trial results demonstrate nemolizumab's rapid onset of action in patients with prurigo nodularis. Galderma Laboratories, L.P. Press release. Published October 26, 2023. Accessed April 18, 2024.

IMPORTANT SAFETY INFORMATION

INDICATIONS: NEMLUVIO^® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for:

the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.
the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are:

Atopic Dermatitis: headache (including migraine), arthralgia, urticaria, and myalgia.
Prurigo Nodularis: headache, dermatitis atopic, eczema, and eczema nummular.

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug- associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of NEMLUVIO have not been established in pediatric patients younger than 12 years of age for the treatment of moderate-to-severe atopic dermatitis or pediatric patients younger than 18 years of age for the treatment of prurigo nodularis.

Please see full Prescribing Information, including Patient Information.

As soon as 48 hours,* NEMLUVIO relieves itch fast, with skin healing that lasts1

A Trial Program Designed to Capture the Complexity of PN2,3

Experiencing a new reality

Sign up now for more information about NEMLUVIO for PN

As soon as 48 hours,* NEMLUVIO relieves itch fast, with skin healing that lasts¹

A Trial Program Designed to Capture the Complexity of PN^2,3